Next Article in Journal
A Simple, Rapid and Mild One Pot Synthesis of Benzene Ring Acylated and Demethylated Analogues of Harmine under Solvent-free Conditions
Previous Article in Journal
5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 13
Issue 8
10.3390/molecules13081570
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

4-Azatricyclo[5.2.2.02,6]undecane-3,5,8-triones as Potential Pharmacological Agents

by
Jerzy Kossakowski
1,
Anna Bielenica
1,
Barbara Mirosław
2,
Anna E. Kozioł
2,
Izabela Dybała
2 and
Marta Struga
1,*
1
Department of Medical Chemistry, The Medical University of Warsaw, 3 Oczki Street, 02-007 Warsaw, Poland
2
Faculty of Chemistry, Maria Curie-Sklodowska University, 20-031 Lublin, Poland
*
Author to whom correspondence should be addressed.
Molecules 2008, 13(8), 1570-1583; https://doi.org/10.3390/molecules13081570
Submission received: 14 May 2008 / Revised: 19 June 2008 / Accepted: 25 July 2008 / Published: 6 August 2008
Browse Figures
Versions Notes

Abstract

:
A series of twenty six arylpiperazine and aminoalkanol derivatives of 4-aza-tricyclo[5.2.2.02,6]undecane-3,5,8-trione have been prepared. The synthesized compounds were evaluated for their cytotoxicity and anti-HIV-1 activity in MT-4 cells.

Introduction

Currently available drugs for the treatment of HIV virus are based on combination of two types of anti-HIV-1 agents: nucleoside reverse transcriptase inhibitors (RTIs) and protease inhibitors [1]. The RTIs can be divided into nucleoside (NI) and non-nucleoside RT inhibitors (NNRTI). Several non-nucleoside inhibitors have been described, including nevirapine, thiobenzimidazolone (TIBO) derivatives, pyridinone derivatives and the bis(heteroaryl)piperazines (BHAPs), such as delavirdine and atevirdine [2]. Another arylpiperazine, vicriviroc, is currently in Phase II clinical trials [3]. However, the application of these agents is limited by serious side effects and the emergence of resistant strains. The discovery of new BHAPs analogs is actively proceeding [4,5]. Moreover, arylpiperazine derivatives exhibit a wide range of other biological activities: antiviral [6,7], anticancer [8,9], antioxidative [10], antibacterial [11] and antiarrythmic [12,13]. Many compounds of this class show high affinity for α1-adrenergic [14], dopaminergic [15] and serotoninergic receptors [16,17].
This work is a continuation of our investigation in the field of long-chain arylpiperazines [19], in a group of 4-azatricyclo[5.2.2.02,6]undecane-3,5,8-trione derivatives. The newly synthesized compounds were evaluated for their inhibitory effects against the HIV-1 multiplication in acutely infected MT-4 cells (investigations performed at the Dipartamento di Scienze e Tecnologie Biomediche, Universita di Cagliari, Monserrato, Italy).

Results and Discussion

The first step of the multistage synthesis was the reaction of cyclohex-2-en-1-one with maleimide, in the presence of p-toluenosulfonic acid and isopropenyl acetate (Scheme 1). 3,5-Dioxo-4-aza-tricyclo[5.2.2.02,6]undec-8-en-8-yl acetate (1) obtained in this reaction was then hydrolyzed by heating with aqueous-ethanolic solution of ammonia to give imide 2.
Molecules 13 01570 g004 550
Scheme 1. Synthesis of derivatives of 4-azatricyclo[5.2.2.02,6]undecane-3,5,8-trione (2).
Scheme 1. Synthesis of derivatives of 4-azatricyclo[5.2.2.02,6]undecane-3,5,8-trione (2).
Molecules 13 01570 g004
By alkylation of the latter with dibromoalkanes and 2-(chloromethyl)oxirane, the respective bromoalkyl- and 4-(oxiran-2-ylmethyl)- derivatives 3–5 were obtained. Next, the compounds were condensed with appropriate amines to give derivatives3a–5j. The general synthetic pathway is given in Scheme 1. The structure of all compounds have been established on the basis of elemental analysis, 1H-NMR and X-ray crystallography of 1, 2 and 5e (Figure 1, Figure 2 and Figure 3).
The molecular geometry adopted in the solid-state by 1, 2 and 5e is influenced by a pattern of intermolecular contacts. The imide part of 1 and 2 is involved in intermolecular N-H···O hydrogen bonds which differentiate two peptide units: N1-C2=O2 and N1-C1=O1, causing the lengthening of the C=O bond and the shortening of C-N distance around the O atom, the latter being a hydrogen bond acceptor. The dimeric association around the center of symmetry is observed in the crystal structure of 1, while molecules 2 form chains. In contrast, the imide moiety of 5e is symmetric having equal respective bond lengths within the (O1)C1-N1-C2(O2) fragment. The hydrocarbon skeleton is rigid.
Molecules 13 01570 g001 550
Figure 1. Molecular structure of starting compound 1. The bond lengths within the imide fragment are: C1-O1 1.206(2), C1-N1 1.383(3), C2-O2 1.217(2), C2-N1 1.365(3), C1-C8 1.505(3), C2-C3 1.507(3), C3-C8 1.541(3) Å.
Figure 1. Molecular structure of starting compound 1. The bond lengths within the imide fragment are: C1-O1 1.206(2), C1-N1 1.383(3), C2-O2 1.217(2), C2-N1 1.365(3), C1-C8 1.505(3), C2-C3 1.507(3), C3-C8 1.541(3) Å.
Molecules 13 01570 g001
Molecules 13 01570 g002 550
Figure 2. Molecular structure of starting compound 2. The bond lengths within the imide fragment are: C1-O1 1.216(2), N1-C1 1.367(2), C2-O2 1.206(2), C2-N1 1.386(2), C2-C3 1.508(2), C1-C8 1.511(2), C8-C3 1.540(2) Å.
Figure 2. Molecular structure of starting compound 2. The bond lengths within the imide fragment are: C1-O1 1.216(2), N1-C1 1.367(2), C2-O2 1.206(2), C2-N1 1.386(2), C2-C3 1.508(2), C1-C8 1.511(2), C8-C3 1.540(2) Å.
Molecules 13 01570 g002
Molecules 13 01570 g003 550
Figure 3. Molecular structure of product 5e. Selected bond lengths: O1-C1 1.199(6), O2 C2 1.220(6), N1-C1 1.390(6), N1-C2 1.396(6), N1-C11 1.449(7), C2-C3 1.497(7), C3-C8 1.551(6), C1-C8 1.511(8) Å.
Figure 3. Molecular structure of product 5e. Selected bond lengths: O1-C1 1.199(6), O2 C2 1.220(6), N1-C1 1.390(6), N1-C2 1.396(6), N1-C11 1.449(7), C2-C3 1.497(7), C3-C8 1.551(6), C1-C8 1.511(8) Å.
Molecules 13 01570 g003
The molecular geometry adopted in the solid-state by 1, 2 and 5e is influenced by a pattern of intermolecular contacts. The imide part of 1 and 2 is involved in intermolecular N-H...O hydrogen bonds which differentiate two peptide units: N1-C2=O2 and N1-C1=O1, causing the lengthening of the C=O bond and the shortening of C-N distance around the O atom being an acceptor of hydrogen bond . The dimeric association around the center of symmetry is observed in the crystal structure of 1, while molecules 2 form chains. In contrast, the imide moiety of 5e is symmetric having equal respective bond lengths within the (O1)C1-N1-C2(O2) fragment. The hydrocarbon skeleton is rigid.
Thirty one new compounds were obtained. The synthesized compounds were evaluated for their cytotoxicity and anti-HIV-1 activity in MT-4 cells. The results are shown in Table 1. None of investigated compounds showed any anti HIV-1 activity, however, their cytotoxicity determined by the MTT method is greater then 100 μM.
Table
Table 1. Cytotoxicity and anti-HIV activity of compounds 2−5j.
Table 1. Cytotoxicity and anti-HIV activity of compounds 2−5j.
CompoundaCC50bEC50
MT-4HIV-1
2, 3, 3a, 3b, 3c, 3d, 3f, 3h,
4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h,
5a, 5b, 5c, 5d, 5e, 5f, 5g, 5h, 5i, 5j
>100
>100
aCompound concentration (μM) required to reduce the viability of mock-infected MT-4 cells by 50%, as determined by the MTT method. bCompound concentration (μM) required to achieve 50% protection of MT-4 cells from the HIV-1 induced cytopathogeneticy, as determined by the MTT method.

Experimental

General

All chemicals and solvents were purchased from Aldrich (Vienna, Austria). Melting points were determined on Electrothermal Digital Melting Point Apparatus (Essex, UK) and are uncorrected. The 1H-NMR spectra were recorded on a Bruker (Rheinstetten, Germany) spectrometer, operating at 400 MHz. The chemical shift values are expressed in ppm relative to TMS as an internal standard. Elemental analyses were recorded on a CHN model 2400 Perkin-Elmer (Hitachi, Tokyo, Japan). TLC was carried out using silica gel 60 F254, layer thickness 0.25 mm (E. Merck, Darmstadt, Germany) and the results were visualized using UV lamp at 254 nm. Column chromatography was carried out using silica gel 60 (200–400 mesh, Merck). The X-ray diffraction data were collected at 295 K with a KM4 diffractometer using graphite monochromated CuKα radiation (λ = 1.54178 Å) and ω/2θ scan mode. structures were solved by the SHELXS-97 program [20] and refined by full-matrix least-squares on F2 using the SHELXL-97 program [21]. Non hydrogen atoms were refined with anisotropic displacement parameters. Carbon-bonded H-atoms were posititoned geometrically and ‘riding’ model was used in the refinement. The H-atoms of the hydroxyl, imide and piperidine groups were located on difference maps. The experimental details and final atomic parameters for 1, 2 and 5e have been deposited with the Cambridge Crystallographic Data Centre as supplementary material under deposition numbers CCDC 659529-659531, respectively. Copies of the data can be obtained free of charge on application to The Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, Fax: +44-1223-336-033; e-mail: [email protected] or www: http://www.ccdc.cam.ac.uk.

Synthesis of 3,5-dioxo-4-azatricyclo[5.2.2.02,6]undec-8-en-8-yl acetate (1)

A mixture of cyclohex-2-en-1-one (0.052 mol), maleimide (0.072 mol) and p-toluenesulfonic acid (50 mg) was refluxed for 6 h in isopropenyl acetate (15 cm3) The liquid was distilled off and the oily residue was crystallized from a hexane-ethyl acetate mixture (1:1) to give imide 1. Yield 75%; m.p. 205–207°C; 1H-NMR (CDCl3) δ (ppm): 1.25–1.3 (m, 1H, CH2), 1.55–1.66 (m, 3H, CH2), 2.09 (s, 3H, CH3), 2.82–2.93 (m, 3H, CH-C=O, CH), 3.02 (d, 1H, J = 3.6 Hz, CH-C=O), 5.67 (d, 1H, J = 6.8 Hz, CH=), 11.08 (s, 1H, NH); Anal. Calcd. for C12H13NO4: C, 61.27, H, 5.57, N, 5.95. Found: C, 61.31, H, 5.69, N, 5.92; Crystal data: crystal system monoclinic, space group P21/n with unit cell dimensions a = 8.662(2) Å, b = 11.884(2) Å, c = 10.754(2) Å, β= 96.22(3)°, V = 1100.5(4) Å3, Z = 4, D(calcd) = 1.420 g/cm3. Independent reflections 2234 [R(int) = 0.0194], number of parameters 155, final R indices [for 1412 reflections with I > 2σ(I)] R1 = 0.0396, wR2 = 0.1086, and for all data R1 = 0.0842, wR2 = 0.1286. Largest residual peak and hole 0.15 and -0.22 e Å-3.

Synthesis of 4-azatricyclo[5.2.2.02,6]undecane-3,5,8-trione (2)

Imide 1 (0.043 mol) was refluxed for 1 h in anhydrous ethanol (80 mL) and 20% ammonia solution (15 mL). The liquid was filtered off and the residue was purified by crystallization from anhydrous ethanol to give compound 2. Yield 74%; m.p. 223–224°C; 1H-NMR (CDCl3) δ (ppm): 1.68–1.94 (m, 5H, CH2, CH2-CH-CH2), 2.29 (d, 1H, J = 19.2 Hz, CH-C=O), 2.46–2.53 (m, 2H, CH2-C=O), 3.02 (dd, 1H, J = 2.3 Hz, CH-C=O), 3.21 (dd, 1H, J = 3.2 Hz, CH-C=O ), 11.35 (s, 1H, NH); Anal. Calcd. for C10H11NO3: C, 62.17, H, 5.72, N, 7.25. Found: C, 62.30, H, 5.8, N, 7.28; Crystal data: crystal system monoclinic, space group P21/c with unit cell dimensions a = 9.941(2) Å, b = 10.628(2) Å, c = 8.300 (2) Å, β = 93.49 (3)°, V = 875.3(3) Å3, Z = 4, D(calcd) = 1.466 g/cm3. Independent reflections 1864 [R(int) = 0.0557], number of parameters 128, final R indices [for 1614 reflections with I > 2σ(I)] R1 = 0.0428, wR2 = 0.1215, and for all data R1 = 0.0496, wR2 = 0.1267; extinction coefficient x = 0.020(2). Largest residual peak and hole 0.28 and -0.18 e Å-3.

General method for preparation of 4-(3-bromopropyl)- and 4-(4-bromobutyl)-4-aza-tricyclo[5.2.2.02,6]undecane-3,5,8-trione (3 and 4)

A mixture of 2 (0.01 mol), 1,4-dibromobutane (0.03 mol) or 1,3-dibromopropane (0.03 mol) and anhydrous K2CO3 (0.014 mol) was dissolved in butanone (100 mL) and refluxed for 20 h. The solvent was distilled off and the oily residue was purified by column chromatography (eluting with chloroform) to give compounds 3 or 4, respectively.
3. Yield 69.5%; m.p. 103–105°C; 1H-NMR (CDCl3) δ (ppm): 1.82 (d, 2H, J = 7.6 Hz, CH2), 1.95 (d, 2H, J = 6.8 Hz, CH2), 2.06–2.1 (m, 3H, CH-CH2, CH2), 2.24–2.29 (m, 1H, CH-CH2), 2.78 (d, 1H, J = 2.8 Hz, CH-C=O), 2.87 (d, 1H, J = 2.8 Hz, CH-C=O), 3.04 (dd, 1H, J = 3 Hz, CH2), 3.14 (dd, 1H, J = 4.1 Hz, CH2), 3.3−3.34 (m, 2H, CH2), 3.57–3.69 (m, 2H, CH2); Anal. Calcd. for C13H16NO3Br: C, 49.70, H, 5.13, N, 4.46. Found: C, 49.66, H, 5.14, N, 4.50.
4. Yield 85%; m.p. 84–86°C; 1H-NMR (CDCl3) δ (ppm): 1.66–1.68 (m, 2H, CH2), 1.73–1.84 (m, 4H, CH2), 1.95–1.98 (m, 2H, CH2), 2.06–2.11 (m, 1H, CH-CH2), 2.24–2.29 (m, 1H, CH-CH2), 2.78 (d, 1H, J = 2.4 Hz, CH2), 2.87 (d, 1H, J = 2.8 Hz, CH2), 3.03 (dd, 1H, J = 2.3 Hz, CH-C=O), 3.13 (dd, 1H, J = 3.1 Hz, CH-C=O), 3.4 (t, 2H, J = 6.2 Hz, CH2), 3.51 (t, 2H, J = 6.8 Hz, CH2); Anal. Calcd. for C14H18NO3Br·½ H2O: C, 49.86, H, 5.68, N, 4.12. Found: C, 49.91, H, 5.30, N, 4.12.

General method for preparation of 4-substituted arylpiperazines with derivatives 3 and 4 (3a–4h)

A mixture of derivative 3 (0.012 mol) or 4 (0.016 mol), an appropriate amine (0.0024 or 0.0032 mol), anhydrous K2CO3 (0.003 mol) and catalytic amount of KI was dissolved in butanone (50 mL) and refluxed for 15 h. The solvent was evaporated, the residue was purified by column chromatography (eluting with chloroform-methanol 99.5:0.5) to give compounds 3a–3h and 4a–4h, respectively.
3a. Yield 80%; m.p. 215–217°C; 1H-NMR (CDCl3) δ (ppm): 1.82–1.83 (m, 4H, CH2), 1.94–1.97 (m, 2H, CH2), 2.08–2.12 (m, 1H, CH-CH2), 2.23–2.28 (m, 1H, CH-CH2 ), 2.42–2.56 (m, 6H, CH2), 2.77 (d, 1H, J = 2.8 Hz, CH-C=O), 2.87 (d, 1H, J = 2.8 Hz, CH-C=O), 3.03 (dd, 1H, J = 3.8 Hz, CH2), 3.14 (dd, 1H, J = 4.2 Hz, CH2), 3.38–3.45 (m, 6H, CH2), 3.76 (s, 3H, OCH3), 6.85–7.01 (m, 4H, CHarom.), 10.88 (s, 1H, HCl); Anal. Calcd. for C24H32ClN3O4·H2O: C, 60.06, H, 7.14, N, 8.76. Found: C, 59.66, H, 7.40, N, 8.87.
3b. Yield 75%; m.p. 117–119°C; 1H-NMR (CDCl3) δ (ppm): 1.82–1.83 (m, 4H, CH2), 1.94–1.97 (m, 2H, CH2), 2.08–2.12 (m, 1H, CH-CH2), 2.23–2.28 (m, 1H, CH-CH2 ), 2.42–2.56 (m, 6H, CH2), 2.77 (d, 1H, J = 2.8 Hz, CH-C=O), 2.87 (d, 1H, J = 2.8 Hz, CH-C=O), 3.03 (dd, 1H, J = 3.8 Hz, CH2), 3.14 (dd, 1H, J = 4.2 Hz, CH2), 3.54 – 3.59 (m, 2H, CH2), 3.86–3.88 (m, 4H, CH2), 6.49 (t, 1H, J = 4.6 Hz, CHarom.β), 8.3 (d, 2H, J = 4.8 Hz, CHarom.α); Anal. Calcd. for C21H27N5O3·½ H2O: C, 62.05, H, 6.94, N, 17.23. Found: C, 62.16, H, 6.75, N, 16.86.
3c. Yield 70%; m.p. 250–252°C; 1H-NMR (CDCl3) δ (ppm): 1.74–1.81 (m, 4H, CH2), 1.92–1.93 (m, 2H, CH2), 2.08–2.12 (m, 1H, CH-CH2), 2.23–2.28 (m, 1H, CH-CH2 ), 2.42–2.56 (m, 6H, CH2), 2.77 (d, 1H, J = 2.8 Hz, CH-C=O), 2.87 (d, 1H, J = 2.8 Hz, CH-C=O), 3.03 (dd, 1H, J = 3.8 Hz, CH2), 3.14 (dd, 1H, J = 4.2 Hz, CH2), 3.38–3.44 (m, 6H, CH2), 6.73–6.89 (m, 4H, CHarom.), 9.23 (s, 1H, OH), 10.45 (s, 1H, HCl); Anal. Calcd. for C23H30ClN3O4: C, 61.67, H, 6.75, N, 9.38. Found: C, 62.02, H, 6.72, N, 9.32.
3d. Yield 72%; m.p. 166–168°C; 1H-NMR (CDCl3) δ (ppm): 1.77–1.82 (m, 4H, CH2), 1.93–1.97 (m, 2H, CH2), 2.07–2.12 (m, 1H, CH-CH2), 2.22–2.27 (m, 1H, CH-CH2 ), 2.41 (t, 2H, J = 7 Hz, CH2), 2.6–2.61 (m, 4H, CH2), 2.76 (d, 1H, J = 2.8 Hz, CH-C=O), 2.86 (d, 1H, J = 2.8 Hz, CH-C=O), 3.0 (dd, 1H, J = 3.8 Hz, CH2), 3.11 (dd, 1H, J = 4.2 Hz, CH2), 3.19–3.22 (m, 4H, CH2), 3.57 (t, 2H, J = 7.2 Hz, CH2), 6.38–6.86 (m, 3H, CHarom.), 7.23–7.27 (m, 2H, CHarom.); Anal. Calcd. for C23H29N3O3: C, 69.85, H, 7.39, N, 10.62. Found: C, 69.34, H, 7.16, N,10.44.
3e. Yield 70%; m.p. 166–168°C; 1H-NMR (CDCl3) δ (ppm): 1.74–1.82 (m, 4H, CH2), 1.94–1.95 (m, 2H, CH2), 2.07–2.12 (m, 1H, CH-CH2), 2.23–2.28 (m, 1H, CH-CH2 ), 2.38 (t, 2H, J = 4.6 Hz, CH2), 2.53–2.55 (m, 4H, CH2), 2.76 (d, 1H, J = 2.8 Hz, CH-C=O), 2.86 (d, 1H, J = 2.8 Hz, CH-C=O), 3.01 (dd, 1H, J = 3.8 Hz, CH2), 3.11 (dd, 1H, J = 4.2 Hz, CH2), 3.53–3.59 (m, 6H, CH2), 6.6–6.65 (m, 2H, CHarom.), 7.29–7.49 (m, 1H, CHarom.), 8.17–8.18 (m, 1H, CHarom.); Anal. Calcd. for C22H28N4O3·½H2O: C, 65.17, H, 7.21, N, 13.82. Found: C, 65.69, H, 6.84, N,13.71.
3f. Yield 73%; m.p. 125–127 °C; 1H-NMR (CDCl3) δ (ppm): 1.82–1.83 (m, 4H, CH2), 1.94–1.96 (m, 2H, CH2), 2.08–2.13 (m, 1H, CH-CH2), 2.24–2.29 (m, 1H, CH-CH2 ), 2.46 (m, 2H, CH2), 2.7–2.72 (m, 4H, CH2), 2.77 (d, 1H, J = 2.8 Hz, CH-C=O), 2.87 (d, 1H, J = 2.8 Hz, CH-C=O), 3.0 (dd, 1H, J = 3.8 Hz, CH2), 3.11 (dd, 1H, J = 4.2 Hz, CH2), 3.14–3.18 (m, 4H, CH2), 3.57 (t, 2H, J = 7.2 Hz, CH2), 6.85–6.97 (m, 4H, CHarom.); Anal. Calcd. for C23H28FN3O3·2H2O: C, 61.46, H, 7.18, N, 9.35. Found: C, 61.70, H, 6.80, N, 9.22.
3g. Yield 65%; m.p. 135–137 °C; 1H-NMR (CDCl3) δ (ppm): 1.71–1.82 (m, 4H, CH2), 1.93–1.96 (m, 2H, CH2), 2.05–2.1 (m, 1H, CH-CH2), 2.22–2.27 (m, 1H, CH-CH2 ), 2.41 (t, 2H, J = 7 Hz, CH2), 2.57–2.61 (m, 5H, CH2), 2.75 (d, 1H, J = 2.8 Hz, CH-C=O), 2.85 (d, 1H, J = 2.8 Hz, CH-C=O), 3.0 (dd, 1H, J = 3.8 Hz, CH2), 3.11 (dd, 1H, J = 4.2 Hz, CH2), 3.19–3.22 (m, 4H, CH2), 3.46–3.67 (m, 4H, CH2), 7.29–7.49 (m, 5H, CHarom.); Anal. Calcd. for C24H32ClN3O3·H2O: C, 62.13, H, 7.39, N, 9.06. Found: C, 62.52, H, 7.18, N, 8.89.
3h. Yield 70%; m.p. 115–117 °C; 1H-NMR (CDCl3) δ (ppm): 1.76–1.83 (m, 4H, CH2), 1.94–1.97 (m, 2H, CH2), 2.08–2.13 (m, 1H, CH-CH2), 2.24–2.27 (m, 1H, CH-CH2 ), 2.28 (s, 3H, CH3), 2.43 (t, 2H, J = 7 Hz, CH2), 2.6–2.64 (m, 4H, CH2), 2.76 (d, 1H, J = 2.8 Hz, CH-C=O), 2.87 (d, 1H, J = 2.8 Hz, CH-C=O), 3.93–3.96 (m, 4H, CH2), 3.0 (dd, 1H, J = 3.8 Hz, CH2), 3.13 (dd, 1H, J = 4.2 Hz, CH2), 3.55−3.59 (m, 2H, CH2), 6.95–7.02 (m, 2H, CHarom.), 7.13–7.17 (m, 2H, CHarom.); Anal. Calcd. for C24H31N3O3: C, 70.39, H, 7.63, N, 10.26. Found: C, 69.99, H, 7.35, N, 10.02.
4a. Yield 80%; m.p. 204–206°C; 1H-NMR (CDCl3) δ (ppm): 1.47–1.54 (m, 2H, CH2), 1.81–1.83 (m, 2H, CH2), 1.94–1.97 (m, 2H, CH2), 2.06–2.11 (m, 1H, CH-CH2), 2.23–2.28 (m, 1H, CH-CH2), 2.48–2.5 (m, 2H, CH2), 2.73–2.77 (m, 6H, CH2), 2.87–2.88 (m, 1H, CH2), 3.0–3.03 (m, 1H, CH-C=O), 3.11–3.14 (m, 1H, CH-C=O), 3.14–3.16 (m, 6H, CH2), 3.49−3.51 (m, 2H, CH2), 3.86 (s, 3H, OCH3), 6.84–7.01 (m, 4H, CHarom.); Anal. Calcd. for C25H34ClN3O4: C, 63.08, H, 7.20, N, 8.83. Found: C, 63.53, H, 7.23, N, 8.87.
4b. Yield 78%; m.p. 139–140°C; 1H-NMR (CDCl3) δ (ppm): 1.47–1.55 (m, 4H, CH2), 1.82–1.83 (m, 2H, CH2), 1.94–1.98 (m, 2H, CH2), 2.06–2.11 (m, 1H, CH-CH2), 2.23–2.28 (m, 1H, CH-CH2), 2.35–2.39 (m, 2H, CH2), 2.46−2.49 (m, 4H, CH2), 2.77 (d, 1H, CH2), 2.87 (d, 1H, CH2), 3.0–3.02 (m, 1H, CH-C=O), 3.1–3.13 (m, 1H, CH-C=O), 3.48–3.52 (m, 2H, CH2), 3.8−3.82 (m, 4H, CH2), 6.47 (t, 1H, J = 4.8 Hz, CHarom. β), 8.3 (d, 2H, J = 4.8 Hz, CHarom. α); Anal. Calcd. for C22H30ClN5O3·½H2O: C, 62.84, H, 7.19, N, 16.66. Found: C, 62.82, H, 6.89, N, 16.37.
4c. Yield 65%; m.p. 243–245 °C; 1H-NMR (CDCl3) δ (ppm): 1.47–1.53 (m, 4H, CH2), 1.63–1.85 (m, 2H, CH2), 1.8–1.82 (m, 2H, CH2), 2.12–2.17 (m, 1H, CH-CH2), 2.24–2.29 (m, 1H, CH-CH2), 2.4–2.41 (m, 2H, CH2), 2.56 (m, 3H, CH2,), 2.9−2.92 (m, 1H, CH2), 3.0–3.01 (m, 4H, CH2), 3.0–3.01 (m, 1H, CH-C=O), 3.02–3.03 (m, 1H, CH-C=O), 3.5–3.51 (m, 4H, CH2), 6.85–7.18 (m, 4H, CHarom.); Anal. Calcd. for C24H32ClN3O4: C, 62.39, H, 6.98, N, 9.10. Found: C, 62.50, H, 6.21, N, 8.89.
4d. Yield 67%; m.p. 200–202°C; 1H-NMR (CDCl3) δ (ppm): 1.48–1.49 (m, 4H, CH2), 1.72–1.8 (m, 2H, CH2), 1.81–1.83 (m, 2H, CH2), 2.06–2.11 (m, 1H, CH-CH2), 2.23–2.28 (m, 1H, CH-CH2), 2.38–2.39 (m, 2H, CH2), 2.56–2.58 (m, 4H, CH2,), 2.77 (d, 1H, CH2), 2.87 (d, 1H, CH2), 2.97–3.01 (m, 1H, CH-C=O), 3.09–3.12 (m, 1H, CH-C=O), 3.19–3.2 (m, 4H, CH2), 2.51–3.53 (m, 2H, CH2), 6.84–6.93 (m, 5H, CHarom.); Anal. Calcd. for C24H33Cl2N3O3·½H2O: C, 58.66, H, 6.97, N, 8.55. Found: C, 58.88, H, 6.76, N, 8.36.
4e. Yield 72%; m.p. 129–130°C; 1H-NMR (CDCl3) δ (ppm): 1.48–1.54 (m, 4H, CH2), 1.75–1.83 (m, 2H, CH2), 1.94–1.96 (m, 2H, CH2), 2.06–2.11 (m, 1H, CH-CH2), 2.24–2.29 (m, 1H, CH-CH2), 2.36–2.39 (m, 2H, CH2), 2.53–2.54 (m, 4H, CH2,), 2.77 (d, 1H, CH2), 2.88 (d, 1H,CH2), 2.99–3.01 (m, 1H, CH-C=O), 3.09–3.12 (m, 1H, CH-C=O), 3.49–3.53 (m, 6H, CH2), 6.59–6.64 (m, 2H, CHarom.), 7.46 (t, 1H, J = 7.2 Hz, CHarom.γ), 8.16 (d, 1H, J = 3.6 Hz, CHarom.α); Anal. Calcd. for C23H30N4O3: C, 67.29, H, 7.37, N, 13.65. Found: C, 66.92, H, 7.16, N, 13.46.
4f. Yield 70%; m.p. 72–74°C; 1H-NMR (CDCl3) δ (ppm): 1.47–1.53 (m, 4H, CH2), 1.82–1.93 (m, 2H, CH2), 1.94–1.95 (m, 2H, CH2), 2.05–2.1 (m, 1H, CH-CH2), 2.22–2.27 (m, 1H, CH-CH2), 2.37–2.4 (m, 2H, CH2), 2.59–2.6 (m, 4H, CH2,), 2.87 (d, 1H, CH2), 2.99 (d, 1H, CH2), 3.01–3.09 (m, 1H, CH-C=O), 3.11–3.12 (m, 3H, CH2, CH-C=O), 3.48–3.51 (m, 2H, CH2), 6.86–6.96 (m, 4H, CHarom.); Anal. Calcd. for C24H31ClFN3O3: C, 62.13, H, 6.73, N, 9.06. Found: C, 62.09, H, 6.75, N, 8.94.
4g. Yield 60%; m.p. 175–177°C; 1H-NMR (CDCl3) δ (ppm): 1.42–1.51 (m, 4H, CH2), 1.8–1.82 (m, 2H, CH2), 1.93–1.95 (m, 2H, CH2), 2.04–2.09 (m, 1H, CH-CH2), 2.21–2.26 (m, 1H, CH-CH2), 2.3–2.34 (m, 2H, CH2), 2.24–2.49 (m, 8H, CH2,), 2.75 (d, 1H, J = 2.4 Hz, CH2), 2.85 (d, 1H, J = 2.8 Hz, CH2), 2.97–3.0 (m, 1H, CH-C=O), 3.08–3.11 (m, 1H, CH-C=O), 3.45–3.49 (m, 4H, CH2), 7.23–7.3 (m, 5H, CHarom.); Anal. Calcd. for C25H34ClN3O3·3H2O: C, 58.41, H, 7.84, N, 8.18. Found: C, 58.63, H, 7.91, N 8.37.
4h. Yield 70%,m.p. 109–110°C, 1H-NMR (CDCl3) δ (ppm): 1.48–1.54 (m, 4H, CH2), 1.81–1.83 (m, 2H, CH2), 1.94–1.96 (m, 2H, CH2), 2.07–2.12 (m, 1H, CH-CH2), 2.13–2.28 (m, 1H, CH-CH2), 2,29 (s, 3H, CH3), 2.38–2.42 (m, 2H, CH2), 2.56–2.58 (m, 4H, CH2,), 2.77 (d, 1H, J = 2.4 Hz, CH2), 2.88 (d, 1H, J = 2.4 Hz, CH2), 2.92–2.93 (m, 4H, CH2), 3.01–3.02 (m, 1H, CH-C=O), 3.12–3.13 (m, 1H, CH-C=O), 3.49–3.52 (m, 2H, CH2), 6.95–7.17 (m, 4H, CHarom.); Anal. Calcd. for C25H33N4O3: C, 70.89, H, 7.85, N, 9.92. Found: C, 70.60, H, 7.62, N, 9.82.

Synthesis of 4-(oxiran-2-ylmethyl)-4-azatricyclo[5.2.2.02,6]undecane-3,5,8-trione (5)

A mixture of imide 2 (0.01 mol), 2-(chloromethyl)oxirane (26 mL) and anhydrous K2CO3 (0.01 mol) was refluxed on water bath for 30 h. The solvent was distilled off, then the oily residue was purified by column chromatography (chloroform-methanol 99.5:0.5). Yield 77.5%; m.p. 172–173.5°C; 1H-NMR (CDCl3) δ (ppm): 1.82–1.84 (m, 2H, CH2), 1.95–1.98 (m, 2H, CH2), 2.21–2.25 (m, 2H, CH2), 2.45–2.67 (m, 1H, CH), 2.72 (t, 1H, J = 4.2 Hz, CH-C=O), 2.77 (d, 1H, J = 4 Hz, CH-C=O), 2.89 (d, 1H, J = 3.2 Hz, CH-C=O), 3.05–3.13 (m, 2H, CH2), 3.16–3.19 (m, 1H, CH-O), 3.58–3.81 (m, 2H, CH2); Anal. Calcd. for C13H15NO4·½H2O: C, 60.46, H, 6.24, N, 5.42. Found: C, 59.95, H, 5.79, N 5.14.

General method for preparation of 4-(amino)-2-hydroxypropyl derivatives of 4-aza-tricyclo[5.2.2.02,6]undecane-3,5,8-trione 5a–5j

A mixture of 5 (0.001 mol), an appropriate amine (0.0015 mol) and water (1 mL) was dissolved in methanol (40 mL) and heated on water bath in 75°C for 20 h. The liquid was distilled off, the oily residue was purified by column chromatography (chloroform-methanol 99.5:0.5) to give compounds 5a–5j.
5a. Yield 60%; m.p. 260–262°C; 1H-NMR (CDCl3) δ (ppm): 1.28 (s, 9H, CH3), 1.68–1.78 (m, 2H, CH2), 1.94–1.98 (m, 2H, CH2), 2.24–2.26 (m, 2H, CH2), 2.43–2.53 (m, 2H, CH2), 2.74–2.8 (m, 1H, CH-C=O), 2.82–2.88 (m, 2H, CH-C=O), 3.06–3.2 (m, 2H, CH2), 3.51–3.79 (m, 2H, CH2), 3.87–3.88 (m, 1H, CH-OH), 5.67 (s, 1H, OH), 8.49 (s, 1H, NH), 8.99 (s, 1H, HCl); Anal. Calcd. for C17H27ClN2O4: C, 56.90, H, 7.58, N, 7.81. Found: C, 56.47, H, 7.37, N, 7.65.
5b. Yield 65%; m.p. 206–208°C; 1H-NMR (CDCl3) δ (ppm): 1.09 (d, 6H, J = 6 Hz, CH3); 1.8–1.83 (m, 2H, CH2); 1.94–1.98 (m, 2H, CH2); 2.24–2.26 (m, 2H, CH2); 2.43–2.53 (m, 3H, CH2, CH); 2.74–2.8 (m, 1H, CH-C=O); 2.82–2.88 (m, 3H, CH, CH-C=O); 3.06–3.2 (m, 2H, CH2), 3.51–3.79 (m, 2H, CH2); 3.87–3.88 (m, 1H, CH-OH); Anal. Calcd. for C16H25ClN2O4: C, 55.73; H, 7.31; N, 8.12. Found: C, 55.30; H, 7.15; N, 7.84.
5c. Yield 60%; m.p. 72–74°C; 1H-NMR (CDCl3) δ (ppm): 1.28 (s, 9H, CH3); 1.67–1.76 (m, 2H, CH2); 1.81–2.05 (m, 2H, CH2); 2.24–2.26 (m, 2H, CH2); 2.43–2.53 (m, 3H, CH2, CH); 2.47 (s, 6H, CH3); 2.74–2.8 (m, 1H, CH-C=O); 2.82–2.88 (m, 2H, CH-C=O); 3.06–3.2 (m, 2H, CH2), 3.51–3.79 (m, 2H, CH2); 3.87–3.88 (m, 1H, CH-OH); Anal. Calcd. for C15H23ClN2O4·1½H2O: C, 50.35; H, 7.32; N, 7.83. Found: C, 50.05; H, 7.00; N, 7.49.
5d. Yield 72%; m.p. 121–123°C; 1H-NMR (CDCl3) δ (ppm): 1.06–1.14 (m, 6H, CH3), 1.8–1.82 (m, 2H, CH2), 1.94–1.97 (m, 2H, CH2), 2.24–2.26 (m, 2H, CH2), 2.43–2.53 (m, 3H, CH2, CH), 2.74–2.8 (m, 5H, CH2, CH-C=O), 2.82–2.88 (m, 2H, CH-C=O), 3.06–3.17 (m, 2H, CH2), 3.52–3.75 (m, 2H, CH2), 3.86–3.84 (m, 1H, CH-OH); Anal. Calcd. for C17H26N2O4·1/3H2O: C, 62.17, H, 8.18, N, 8.53. Found: C, 62.40, H, 7.87, N, 8.41.
5e. Yield 75.5%; m.p. 132–134°C; 1H-NMR (CDCl3) δ (ppm): 1.47–1.49 (m, 2H, CH2), 1.66−1.69 (m, 4H, CH2), 1.8–1.83 (m, 2H, CH2), 1.95–1.97 (m, 2H, CH2), 2.24–2.26 (m, 2H, CH2), 2.43–2.53 (m, 5H, CH2, CH), 2.74–2.8 (m, 1H, CH-C=O), 2.72–2.87 (m, 3H, CH2, CH-C=O), 3.05–3.17 (m, 2H, CH2), 3.51–3.79 (m, 2H, CH2), 4.13–3.91 (m, 1H, CH-OH); Anal. Calcd. for C18H26N2O4: C, 64.65, H, 7.84, N, 8.38. Found: C, 64.35, H, 7.62, N, 8.32; Crystal data: crystal system monoclinic, space group Pc with unit cell dimensions a = 12.496(2) Å, b = 6.242(1) Å, c = 11.351(2) Å, β = 94.36 (3)°, V = 882.8(3) Å3, Z = 2, D(calcd) = 1.258 g/cm3. Independent reflections 1852, number of parameters 215, final R indices [for 986 reflections with I > 2σ(I)] R1 = 0.0601, wR2 = 0.1336, and for all data R1 = 0.1361, wR2 = 0.1656. Largest residual peak and hole 0.31 and -0.30 e Å-3.
5f. Yield 75.5%; m.p. 120–122°C; 1H-NMR (CDCl3) δ (ppm): 0.91 (d, 3H, J = 6.4 Hz, CH3), 1.23–1.39 (m, 3H, CH2, CH), 1.57–1.65 (m, 2H, CH2), 1.8–1.83 (m, 2H, CH2), 1.94–1.96 (m, 2H, CH2), 2.24–2.26 (m, 2H, CH2), 2.33–2.44 (m, 2H, CH2), 2.43–2.53 (m, 3H, CH2, CH), 2.74–2.8 (m, 1H, CH-C=O), 2.82–2.88 (m, 3H, CH, CH-C=O), 3.06–3.2 (m, 2H, CH2), 3.51–3.79 (m, 2H, CH2), 3.87–3.88 (m, 1H, CH-OH); Anal. Calcd. for C19H28N2O4: C, 65.49, H, 8.10, N, 8.04. Found: C, 65.39, H, 7.91, N, 7.99.
5g. Yield 70%; m.p. 186−188°C; 1H-NMR (CDCl3) δ (ppm): 1.66–1.79 (m, 2H, CH2), 1.98–2.05 (m, 3H, CH, CH2), 2.19–2.24 (m, 1H, CH-C=O), 2.47–2.56 (m, 2H, CH2), 3.11–3.15 (m, 6H, CH2), 3.29–3.58 (m, 2H, CH-C=O), 3.6–3.75 (m, 6H, CH2), 4.21–4.24 (m, 1H, CH-OH), 6.82 (t, 1H, J = 7.2 Hz, CHarom.), 6.94 (d, 2H, J = 8.4 Hz, CHarom.), 7.22 (t, 2H, J = 7.8 Hz, CHarom.), 10.67 (s, 1H, HCl); Anal. Calcd. for C23H30ClN3O4: C, 61.67, H, 6.75, N, 9.38. Found: C, 61.39, H, 6.50, N, 9.16.
5h. Yield 80%; m.p. 211–213°C; 1H-NMR (CDCl3) δ (ppm): 1.78–1.82 (m, 2H, CH2), 1.95–1.98 (m, 3H, CH, CH2), 2.21–2.57 (m, 3H, CH-C=O, CH2), 2.74–2.88 (m, 6H, CH2), 3.07–3.16 (m, 6H, CH-C=O, CH2), 3.58–3.63 (m, 2H, CH2), 4.09 (m, 1H, CH-OH), 6.86–6.95 (m, 4H, CHarom.); Anal. Calcd. for C23H28N3O4F: C, 64.32, H, 6.57, N, 9.79. Found: C, 63.94, H, 6.30, N, 9.51.
5i. Yield 75%; m.p. 153–155°C; 1H-NMR (CDCl3) δ (ppm): 1.82–1.84 (m, 2H, CH2), 1.94–1.97 (m, 2H, CH2), 2.28–2.32 (m, 1H, CH), 2.35–2.43 (m, 3H, CH-C=O, CH2), 2.58–2.88 (m, 6H, CH2), 3.06 (d, 1H, J = 8.8 Hz, CH-C=O), 3.16 (d, 1H, J = 8.8 Hz, CH-C=O), 3.53–3.58 (m, 6H, CH2), 3.95–4.05 (m, 1H, CH-OH), 6.25 (m, 2H, CHarom.), 7.47 (t, 1H, J = 7.4 Hz, CHarom.), 8.18 (d, 1H, J = 4 Hz, CHarom.); Anal. Calcd. for C22H28N4O4·½H2O: C, 62.69, H, 6.93, N, 13.29. Found: C, 62.92, H, 6.54, N, 12.88.
5j. Yield 75%; m.p. 147–149°C; 1H-NMR (CDCl3) δ (ppm): 1.81–1.83 (m, 2H, CH2), 1.96–1.98 (m, 2H, CH2), 2.2–2,37 (m, 2H, CH, CH-C=O), 2.55–2.66 (m, 2H, CH2), 2.77–3.19 (m, 12H, CH2, CH-C=O), 3.6–3.75 (m, 2H, CH2), 3.85 (s, 3H, OCH3), 4.08–4.24 (m, 1H, CH-OH), 6.82–7.01 (m, 4H, CHarom.); Anal. Calcd. for C24H31N3O5: C, 65.29, H, 7.08, N, 9.52. Found: C, 65.26, H, 6.76, N, 9.12.

Biological Assays: Compounds

Compounds were dissolved in DMSO at 100 mM and then diluted in the culture medium.

Cells and Viruses

Cell lines were purchased from American Type Culture Collection (ATCC). The absence of mycoplasma contamination was checked periodically by the Hoechst staining method. Cell lines supporting the multiplication of RNA viruses were the following: CD4+ human T-cells containing an integrated HTLV-1 genome (MT-4).

Cytotoxicity Assays

For cytotoxicity evaluations, exponentially growing cells derived from human haematological tumors [CD4+ human T-cells containing an integrated HTLV-1 genome (MT-4)] were seeded at an initial density of 1×105 cells/mL in 96 well plates in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), 100 units/mL penicillin G and 100 µg/mL streptomycin. Cell cultures were then incubated at 37°C in a humidified, 5% CO2 atmosphere in the absence or presence of serial dilutions of test compounds. Cell viability was determined after 96 hrs at 37°C by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method [22].

Antiviral assay

Activity of compounds against Human Immunodeficiency virus type-1 (HIV-1) was based on inhibition of virus-induced cytopathogenicity in MT-4 cells acutely infected with a multiplicity of infection (m.o.i.) of 0.01. Briefly, 50 μL of RPMI containing 2×104 MT-4 were added to each well of flat-bottom microtitre trays containing 50 μL of RPMI, without or with serial dilutions of test compounds. Then, 20 μL of an HIV-1 suspension containing 100 CCID50 were added. After a 4-day incubation, cell viability was determined by the MTT method.

Acknowledgments

Authors are grateful to Professor Paolo La Colla for screening of compounds against HIV-1.

References

  1. Carpenter, C.C.; Fischl, M.A.; Hammer, S.M.; Hirsch, M.S.; Jacobsen, D.M.; Katzenstein, D.A.; Montaner, J.S.; Richman, D.D.; Saag, M.S.; Schooley, R.T.; Thompson, M.A.; Vella, S.; Yeni, P.G.; Volberding, P.A. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. J. Am. Med. Assoc. 1998, 280, 78–86. [Google Scholar] [CrossRef]
  2. Romero, D.L.; Morge, R.A.; Genin, M.J.; Biles, C.; Busso, M.; Resnick, L.; Althaus, I.W.; Reusser, F.; Thomas, R.C.; Tarpley, W.G. Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)-amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem. 1993, 36, 1505–1508. [Google Scholar] [CrossRef]
  3. Gulick, R.M.; Su, Z.; Flexner, C.; Hughes, M.D.; Skolnik, P.R.; Wilkin, T.J.; Gross, R.; Krambrink, A.; Coakley, E.; Greaves, W.L.; Zolopa, A.; Reichman, R.; Godfrey, C.; Hirsch, M.; Kuritzkes, D.R. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 2007, 196, 304–312. [Google Scholar] [CrossRef]
  4. Pinna, G.A.; Loriga, G.; Murineddu, G.; Grella, G.; Mura, M.; Vargiu, L.; Murgioni, C.; La Colla, P. Synthesis and anti-HIV-1 activity of new delavirdine analogues carrying arylpyrrole moieties. Chem. Pharm. Bull. 2001, 49, 1406–1411. [Google Scholar] [CrossRef]
  5. Tagat, J.R.; McCombie, S.W.; Nazareno, D.; Labroli, M.A.; Xiao, Y.; Steensma, R.W.; Strizki, J.M.; Baroudy, B.M.; Cox, K.; Lachowicz, J.; Varty, G.; Watkins, R. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. 2004, 47, 2405–2408. [Google Scholar] [CrossRef]
  6. Richter, S.; Parolin, C.; Palumbo, M.; Palu, G. Antiviral properties of quinolone-based drugs. Curr. Drug. Targets Infect. Disord. 2004, 4, 111–116. [Google Scholar] [CrossRef]
  7. Chan, T.M.; Cox, K.; Feng, W.; Miller, M.W.; Weston, D.; McCombie, S.W. Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors. U.S. Pat. 2006223821, 2006. [Google Scholar]
  8. Filosa, R.; Peduto, A.; de Caprariis, P.; Saturnino, C.; Festa, M.; Petrella, A.; Pau, A.; Pinna, G.A.; La Colla, P.; Busonera, B.; Loddo, R. Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)-pyridin-4-yl]methyl-piperazine. Eur. J. Med. Chem. 2007, 42, 293–306. [Google Scholar]
  9. Shaw, Y.J.; Yang, Y.T.; Garrison, J.B.; Kyprianou, N.; Chen, C.S. Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J. Med. Chem. 2004, 47, 4453–4462. [Google Scholar] [CrossRef]
  10. Kimura, M.; Masuda, T.; Yamada, K.; Kawakatsu, N.; Kubota, N.; Mitani, M.; Kishii, K.; Inazu, M.; Kiuchi, Y.; Oguchi, K.; Namiki, T. Antioxidative activities of novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter. Bioorg. Med. Chem. Lett. 2004, 14, 4287–4290. [Google Scholar] [CrossRef]
  11. Foroumadi, A.; Emami, S.; Hassanzadeh, A.; Rajaee, M.; Sokhanvar, K.; Moshafi, M.H.; Shafiee, A. Synthesis and antibacterial activity of N-(5-benzylthio-1,3,4-thiadiazol-2-yl) and N-(5-benzylsulfonyl-1,3,4-thiadiazol-2-yl)piperazinyl quinolone derivatives. Bioorg. Med. Chem. Lett. 2005, 15, 4488–4492. [Google Scholar] [CrossRef]
  12. Bartok, M.; Felfoldi, K.; Karpati, E.; Molnar, A.; Szporny, L. 3-[4-(2'-Pyridyl)-piperazin-1-yl]-1-(3,4,5-trimethoxybenzoyloxy)-propane or a pharmaceutically acceptable acid-addition salt thereof in a composition with anti-arrhythmic activity. U.S. Pat. US4196206, 1980. [Google Scholar]
  13. Mlynárová, R.; Tazká, D.; Racanská, E.; Kyselovic, J.; Svec, P. Effects of a (fluorophenyl) piperazine derivative (substance IIIv) on cardiovascular function. Ceska Slov. Farm. 2000, 49, 177–180. [Google Scholar]
  14. Cecchetti, V.; Schiaffella, F.; Tabarrini, O.; Fravolini, A. (1,4-Benzothiazinyloxy) alkylpiperazine derivatives as potential antihypertensive agents. Bioorg. Med. Chem. Lett. 2000, 10, 465–468. [Google Scholar] [CrossRef]
  15. Dutta, A.K.; Venkataraman, S.K.; Fei, X.S.; Kolhatkar, R.; Zhang, S.; Reith, M.E. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors. Bioorg. Med. Chem. 2004, 12, 4361–4373. [Google Scholar] [CrossRef]
  16. Betti, L.; Zanelli, M.; Giannaccini, G.; Manetti, F.; Schenone, S.; Strappaghetti, G. Synthesis of new piperazine-pyridazinone derivatives and their binding affinity toward alpha1-, alpha2-adrenergic and 5-HT1A serotoninergic receptors. Bioorg. Med. Chem. 2006, 14, 2828–2836. [Google Scholar] [CrossRef]
  17. Obniska, J.; Kołaczkowski, M.; Bojarski, A.J.; Duszyńska, B. Synthesis, anticonvulsant activity and 5-HT1A, 5-HT2A receptor affinity of new N-[(4-arylpiperazin-1-yl)-alkyl] derivatives of 2-azaspiro[4.4]nonane and [4.5]decane-1,3-dione. Eur. J. Med. Chem. 2006, 41, 874–881. [Google Scholar] [CrossRef]
  18. Tandon, M.; O'Donnell, M.M.; Porte, A.; Vensel, D.; Yang, D.; Palma, R.; Beresford, A.; Ashwell, M.A. The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands. Bioorg. Med. Chem. Lett. 2004, 14, 1709–1712. [Google Scholar] [CrossRef]
  19. Kossakowski, J.; Raszkiewicz, A.; Bugno, R.; Bojarski, A.J. Introduction of a new complex imide system into the structure of LCAPs. The synthesis and a 5-HT1A, 5-HT2A and D2 receptor binding study. Pol. J. Pharmacol. 2004, 56, 843–848. [Google Scholar]
  20. Sheldrick, G.M. Shelxs-97. In Program for a crystal structure solution; University of Göttingen: Göttingen , Germany, 1997.
  21. Sheldrick, G.M. Shelxl-97. In Program for the refinement of a crystal structure from diffraction data; University of Göttingen: Göttingen, Germany, 1997.
  22. Pawels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyster, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Meth. 1988, 20, 309–321. [Google Scholar] [CrossRef]
  • Sample Availability: Contact the authors.

Share and Cite

MDPI and ACS Style

Kossakowski, J.; Bielenica, A.; Mirosław, B.; Kozioł, A.E.; Dybała, I.; Struga, M. 4-Azatricyclo[5.2.2.02,6]undecane-3,5,8-triones as Potential Pharmacological Agents. Molecules 2008, 13, 1570-1583. https://doi.org/10.3390/molecules13081570

AMA Style

Kossakowski J, Bielenica A, Mirosław B, Kozioł AE, Dybała I, Struga M. 4-Azatricyclo[5.2.2.02,6]undecane-3,5,8-triones as Potential Pharmacological Agents. Molecules. 2008; 13(8):1570-1583. https://doi.org/10.3390/molecules13081570

Chicago/Turabian Style

Kossakowski, Jerzy, Anna Bielenica, Barbara Mirosław, Anna E. Kozioł, Izabela Dybała, and Marta Struga. 2008. "4-Azatricyclo[5.2.2.02,6]undecane-3,5,8-triones as Potential Pharmacological Agents" Molecules 13, no. 8: 1570-1583. https://doi.org/10.3390/molecules13081570

APA Style

Kossakowski, J., Bielenica, A., Mirosław, B., Kozioł, A. E., Dybała, I., & Struga, M. (2008). 4-Azatricyclo[5.2.2.02,6]undecane-3,5,8-triones as Potential Pharmacological Agents. Molecules, 13(8), 1570-1583. https://doi.org/10.3390/molecules13081570

Article Metrics

Back to TopTop